Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 9/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1909686 | 0.88 | RAB9A (0.61) | SCDSMN1; SMN2HDAC1L3MBTL1POLB | |
| SCHEMBL1909621 | 0.88 | HDAC1 (0.49) | SCDSMN1; SMN2HDAC1L3MBTL1SCN9A | |
| SCHEMBL244590 | 0.87 | SCD (0.50) | SCDHDAC1L3MBTL1RAB9A | |
| SCHEMBL244363 | 0.86 | SCD (0.66) | SCDSMN1; SMN2HDAC1L3MBTL1KMT2A | |
| SCHEMBL240604 | 0.84 | HDAC1 (0.53) | SCDSMN1; SMN2HDAC1L3MBTL1POLB | |
| SCHEMBL242643 | 0.82 | HDAC1 (0.49) | SCDHDAC1RAB9A | |
| SCHEMBL1909592 | 0.82 | SCD (0.45) | SCDSMN1; SMN2HDAC1L3MBTL1POLB | |
| SCHEMBL13557143 | 0.82 | SCD (0.45) | SCDSMN1; SMN2HDAC1L3MBTL1POLB | |
| SCHEMBL1909601 | 0.81 | NPC1 (0.58) | SMN1; SMN2L3MBTL1ROCK2KMT2ARAB9A | |
| SCHEMBL30788554 | 0.79 | MAOB (0.46) | SCDSMN1; SMN2L3MBTL1KMT2ATAS2R8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293768-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120014906-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20120004164-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004164-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885SMN1; SMN2 3581/4885HDAC1 136/4885 |
| US-20120014906-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885SMN1; SMN2 3581/4885HDAC1 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.